Health-Related Quality of Life Changes in Prostate Cancer Patients after Radical Prostatectomy: A Longitudinal Cohort Study

Shin, Dong Wook; Lee, Sang Hyub; Kim, Tae‐Hwan; Yun, Seok Joong; Nam, Jong Kil; Jeon, Seung Hyun; Park, Seung Chol; Jung, Seung Il; Park, Jong Hyock; Park, Jinsung

doi:10.4143/crt.2018.221

Cited by 17 publications

(17 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, we noted a slight but significant reduction (improvement) of the psychological subscore (irritability, nervousness, and anxiety) of the AMS (0.58, 95% CI: 0.25–0.91; P = 0.0003) 1 year after radical prostatectomy. This result is in line with the improved emotional and cognitive functioning 12 months after radical prostatectomy reported in a prospective longitudinal cohort ( n = 209) of prostate cancer patients treated with radical prostatectomy, 23 possibly consequent to patients' relief as the expected that the malignant tumor had been removed. One should be aware that this improvement was not sufficient to compensate for the sexual dysfunction as shown by the worsening of the global AMS score.…”

Section: Discussionsupporting

confidence: 84%

Metabolic syndrome, levels of androgens, and changes of erectile dysfunction and quality of life impairment 1 year after radical prostatectomy

Rouanne

Dreyfus

Raynaud

et al. 2021

Asian Journal of Andrology

View full text Add to dashboard Cite

Robust data evaluating the association of preoperative parameters of the patients with quality of life after radical prostatectomy are lacking. We investigated whether clinical and biological preoperative characteristics of the patients were associated with impaired patient-reported quality of life (QoL) and sexual outcomes 1 year after radical prostatectomy. We evaluated patient-reported outcomes among the 1343 men participating in the AndroCan trial (NCT02235142). QoL and erectile dysfunction (ED) were assessed before and 1 year after radical prostatectomy using validated self-assessment questionnaires (Aging Male's Symptoms [AMS] and the 5-item abridged version of the International Index of Erectile Function [IIEF5]). At baseline, 1194 patients (88.9%) accepted to participate. A total of 750 (55.8%) patients answered the 1-year postoperative questionnaires. Out of them, only 378 (50.4% of responders) provided answers that could be used for calculations. One year after prostatectomy, ED had worsened by 8.0 (95% confidence interval [CI]: 7.3–8.7; P < 0.0001) out of a maximum of 20. The global AMS score has worsened by 2.8 (95% CI: 1.7–3.8; P < 0.0001). ED scores 1 year postsurgery were positively correlated with preoperative age and percentage of fat mass, and negatively correlated with total cholesterol, dehydroepiandrosterone (DHEA), and androstenediol (D5); AMS were poorly correlated with preoperative parameters. QoL and sexual symptoms significantly worsened after radical prostatectomy. Baseline bioavailable testosterone levels were significantly correlated with smaller changes on AMS somatic subscores postprostatectomy. These findings may be used to inform patients with newly diagnosed prostate cancer.

show abstract

Section: Discussionsupporting

confidence: 84%

Metabolic syndrome, levels of androgens, and changes of erectile dysfunction and quality of life impairment 1 year after radical prostatectomy

Rouanne

Dreyfus

Raynaud

et al. 2021

Asian Journal of Andrology

View full text Add to dashboard Cite

show abstract

“… 53 Similarly, a previous cohort study showed a significant improvement in most health-related quality of life domains 12 months after treatment of prostate cancer. 54 In contrast, another study by Klein et al reported a lower health-related quality of life on an overall global scale and all functional domains of quality of life. 55 In addition, a Korean study revealed a lack of improvement in urinary and sexual outcomes in prostate cancer patients after 12 months of treatment.…”

Section: Discussionmentioning

confidence: 90%

Treatment Outcomes and Its Associated Factors Among Adult Patients with Selected Solid Malignancies at Kenyatta National Hospital: A Hospital-Based Prospective Cohort Study

Degu¹,

Terefe²,

Some³

et al. 2022

CMAR

View full text Add to dashboard Cite

Introduction The treatment outcome of cancer is poor in the African setting due to inadequate treatment and diagnostic facilities. However, there is a paucity of data on solid cancers in Kenya. Hence, this study aimed to investigate the treatment outcomes and its determinant factors among adult patients diagnosed with selected solid malignancies at Kenyatta National Hospital (KNH). Materials and Methods A prospective cohort study was employed at the Oncology Department of KNH from 1 st July 2020 to 31 st December 2021. All new patients with a confirmed diagnosis of lymphoma, prostate cancer and breast cancer were studied. A consecutive sample of 99 breast cancer, 50 lymphomas, and 82 prostate cancer patients was included in the study. Semi-structured questionnaires consisting of socio-demographics, clinical characteristics, and quality of life were employed to collect the data. All enrolled patients were followed prospectively for 12 months. Treatment outcomes were reported as mortality, cancer-specific survival and health-related quality of life. The data were entered and analyzed using the SPSS 20.0 statistical software. Survival outcomes and its predictors were evaluated using the Kaplan–Meier analysis and Cox regression analyses, respectively. Results The study showed that the mortality rate among breast and prostate cancer patients was 3% and 4.9%, respectively. In contrast, the mortality rate was 10% among lymphoma patients. Most of the patients had partial remission and a good overall global health-related quality of life. Older age above 60 years, co-morbidity, distant metastasis and advanced stages of disease were significant predictors of mortality. Conclusion Although the mortality was not high at 12 months, only a few patients had complete remission. For many patients, the disease was progressing, despite 12-month mortality was not high. Therefore, longer follow-up will be required to report cancer mortality accurately. In addition, most of the patients had a good overall global health-related quality of life.

show abstract

“…The long-term ADT group, maintained on androgen suppression for 2.5 years, showed further decrease in the functional levels, whereas the short-term group, which discontinued ADT after 6 months, showed no further decrease. 18 Meanwhile, Shin et al 19 conducted a study on the change in the HRQOL according to surgical treatment in patients with PC and reported that surgery had no negative effect on the QLQ-C30 functional scale score over a time period of 1 year, except for the deterioration of the role function. Role function had a temporary decline at 3 months after surgery but returned to baseline at 12 months.…”

Section: Discussionmentioning

confidence: 99%

“…Shin et al. 19 reported that the PC-specific HRQOL of Korean patients, as assessed using the EORTC QLQ-PR25, showed a significant deterioration of most symptom scores, with the exception of bowel symptoms, at 3 months postoperatively compared with the baseline condition after radical prostatectomy. The urinary symptoms worsened at 3 months, and incontinence significantly worsened at 3 months, although patients recovered to nearly the baseline status at 12 months.…”

Section: Discussionmentioning

confidence: 99%

Effects of leuprolide acetate on the quality of life of patients with prostate cancer: A prospective longitudinal cohort study

Kim

Jung

Chung

et al. 2021

Prostate International

Self Cite

View full text Add to dashboard Cite

Purpose The aim of this study was to investigate the effect of androgen deprivation therapy (ADT) on the health-related quality of life (HRQOL) of patients with prostate cancer (PC) and compare the changes in the HRQOL between ADT alone and ADT plus intensity-modulated radiation therapy (IMRT). Materials and methods Patients with PC were prospectively recruited between October 2018 and April 2020. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire and the PC-specific module (PR25) were administered before ADT (baseline) and at 3, 6, and 12 months after ADT. All patients received subcutaneous injections of 45 mg leuprolide acetate at 6-month intervals for 12 months. Results Fifty-five of the 71 patients (77.5%) completed the 12-month study. Twenty-two of the 55 patients received IMRT. There were no differences in the baseline characteristics with respect to IMRT. Compared with baseline, physical function and role function deteriorated after 3 months (p = 0.003, p = 0.019). However, the global quality of life (QOL) did not change over time. The symptom scales of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire indicated that there was a statistically significant deterioration in dyspnea and fatigue symptoms at 12 months (p = 0.004, p = 0.004). Responses to the QLQ-PR25 revealed that patients experienced an increase in hormonal treatment-related symptoms after 3, 6, and 12 months (p = 0.002, 0.001, and 0.004). Comparisons between the ADT group and ADT plus IMRT group showed that body function and role function did not differ between the two groups (p = 0.815, p = 0.759), and there was also no difference in global QOL (p = 0.624). Conclusion Our results indicate that treatment with leuprolide acetate at 6-month intervals was not accompanied by changes in global QOL, despite deterioration of body and role functions and hormonal treatment-related symptoms. The combination of ADT and IMRT did not lead to additional deterioration in the HRQOL.

show abstract

Health-Related Quality of Life Changes in Prostate Cancer Patients after Radical Prostatectomy: A Longitudinal Cohort Study

Abstract: Most HRQOL domains showed recovery within 12 months after RP, excluding sexual functioning and social functioning. Our findings may guide patients considering surgical treatment for PC.

Cited by 17 publications

References 33 publications

Metabolic syndrome, levels of androgens, and changes of erectile dysfunction and quality of life impairment 1 year after radical prostatectomy

Metabolic syndrome, levels of androgens, and changes of erectile dysfunction and quality of life impairment 1 year after radical prostatectomy

Treatment Outcomes and Its Associated Factors Among Adult Patients with Selected Solid Malignancies at Kenyatta National Hospital: A Hospital-Based Prospective Cohort Study

Effects of leuprolide acetate on the quality of life of patients with prostate cancer: A prospective longitudinal cohort study

Contact Info

Product

Resources

About